NCT05478720
DON in Pediatric Cerebral Malaria
At risk: Primary completion moved at least 1 year 11 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Dec 2026 to Nov 30, 2028 Show 4 more changesShow less
- Eligibility criteria expanded, about 40 words
- Secondary endpoints: details revised at 1 of 8 entries
- Study description revised
- Publications: details revised at 2 of 2 entries
Notable Primary and study completion dates: Dec 2025 to Dec 2026v9 Show 4 more changesShow less
- Eligibility criteria shortened, about 17 words
- Primary endpoints: 3 to 4
- Publications: details revised at 1 of 2 entries
- Study description expanded, about 2 words
- Minor Study description shortened, about 7 wordsv8
- Notable Eligibility criteria expanded, about 31 words
- Site details revised at 2 of 2 sites
- Study description shortened, about 2 words
- Minor Enrollment target: 150 to 152
- Interventions: 6-diazo-5-oxo-L-norleucine (DON) (Drug), Placebo (Drug) to 6-diazo-5-oxo-L-norleucine (DON) (Drug), 6-diazo-5-oxo-L-norleucine (DON) (Drug), Placebo (Drug)
- Study description expanded, about 369 words
Show 3 earlier versionsHide 3 earlier versions
Notable Enrollment target: 80 to 150v4 Show 7 more changesShow less
- Primary and study completion dates: Dec 2023 to Dec 2025
- Eligibility criteria expanded, about 153 words
- Primary endpoints: 2 to 3
- Study sites: 1 to 2
- Interventions: 6-diazo-5-oxo-L-norleucine (DON) (Drug) to 6-diazo-5-oxo-L-norleucine (DON) (Drug), Placebo (Drug)
- Study arms: 8 to 13
- Study title shortened, about 3 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Jul 2022 to Aug 16, 2022
- Minor Study title shortened, about 6 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (8)
Show 3 moreShow less
Arms and interventions
The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
After adult doses are shown to be safe. Of the first 6 children with cerebral malaria enrolled, 4 will receive 0.1 mg/kg IV DON, and 2 will receive placebo.
10 participants will receive 0.1 mg/kg IV DON, and 2 will receive placebo.
14 participants will receive 1.0 mg/kg IV DON, and 4 will receive placebo.
36 participants will receive 0.1 mg/kg IV DON (n=12) or 1.0 mg/kg IV DON (n=12), and 12 will receive placebo.
Cohort 1 will dose 2 participants to receive placebo Cohort 2 will dose 2 participants to receive placebo Cohort 3 will dose 4 participants to receive placebo Cohort 4 will dose 12 participants to receive placebo
Drugs: 6-diazo-5-oxo-L-norleucine (DON), Placebo
Sites
2 sites in 1 country